SOPHARMASOPHARMASOPHARMA

SOPHARMA

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.20 B‬PLN
‪211.77 M‬PLN
‪4.17 B‬PLN
‪45.40 M‬
Beta (1Y)

About SOPHARMA AD BGN1


CEO
Ognian Ivanov Donev
Headquarters
Sofia
Founded
1933
ISIN
BG11SOSOBT18
FIGI
BBG002976FB8
Sopharma AD engages in the provision of pharmaceutical business. Its operations include production and marketing of medical products, medicinal substances as well as dosage forms. It also involved in research, engineering, and implementation activities in the field of phytochemistry, chemistry, and pharmacy. The firm offers dermatological products, gastroenterological, as well as psychoneurological, antiallergic and others. The company was founded in 1933 and is headquartered in Sofia, Bulgaria.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Frequently Asked Questions


The current price of SPH is 12.65 PLN — it hasn't changed in the past 24 hours. Watch SOPHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange SOPHARMA stocks are traded under the ticker SPH.
SPH stock has risen by 2.43% compared to the previous week, the month change is a −3.44% fall, over the last year SOPHARMA has showed a −10.92% decrease.
SPH reached its all-time high on Apr 29, 2020 with the price of 23.00 PLN, and its all-time low was 3.50 PLN and was reached on Sep 7, 2012. View more price dynamics on SPH chart.
See other stocks reaching their highest and lowest prices.
Today SOPHARMA has the market capitalization of ‪2.16 B‬, it has decreased by −0.66% over the last week.
Yes, you can track SOPHARMA financials in yearly and quarterly reports right on TradingView.
SOPHARMA is going to release the next earnings report on Nov 29, 2024. Keep track of upcoming events with our Earnings Calendar.
SPH net income for the last quarter is ‪35.62 M‬ PLN, while the quarter before that showed ‪65.27 M‬ PLN of net income which accounts for −45.43% change. Track more SOPHARMA financial stats to get the full picture.
SOPHARMA dividend yield was 17.31% in 2023, and payout ratio reached 135.90%. The year before the numbers were 13.45% and 102.49% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOPHARMA EBITDA is ‪274.78 M‬ PLN, and current EBITDA margin is 8.05%. See more stats in SOPHARMA financial statements.
Like other stocks, SPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOPHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SOPHARMA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SOPHARMA stock shows the neutral signal. See more of SOPHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.